A Mixed Methods Study of Chronic Kidney Disease (CKD) Self-Management

项目摘要 2019年底，由严重急性呼吸系统综合征冠状病毒2（SARS- CoV-2）在中国武汉出现，并迅速影响了全球几乎所有国家。正式 世界卫生组织宣布COVID-19为全球性大流行病，这是一个全球性的紧急情况， 目前的体外模型平台与人类感染如此不同，以至于它们可能无法捕获病毒感染或病毒-宿主相互作用的关键组分。 2020年5月29日，全球报告了超过5. 8例COVID-19病例，超过360，000例死亡。尽管起源于中国，但美国已成为这一大流行病的中心，报告了超过175万例COVID-19病例 超过十万三千人死亡不幸的是，目前还没有疫苗可以预防SARS-CoV-2感染， 激活抗病毒药物，可以减轻感染或改变疾病进展。此外 鉴于这种地方性、国家性和全球性的紧急情况，我们的近期目标是开发新颖而强大的 实验细胞培养模型，病毒学工具，并确定用于SARS-CoV-2治疗的新疗法。 我们的长期目标是阐明SARS-CoV-2感染的复杂相互作用和机制 主机响应。鉴于我们的机构一直处于美国COVID-19大流行的中心， 我们已经建立了一个广泛的临床数据库，揭示了初始COVID-1的高患病率， 19例表现为GI表现，超过一半的患者有生化证据 肝损伤的症状SARS-CoV-2感染对肝细胞和胆管细胞的影响 功能尚不清楚。为了解决这些知识差距，我们开发了几种新技术 并组建了一支强大的团队，在干细胞生物学、组织工程和 病毒学、化学筛选和干细胞生物学以及病毒学/BSL 3专业知识。我们的目标是识别药物 候选人影响SARS-CoV-2病毒感染，而我们评估宿主病毒的相互作用。 鉴于SARS-CoV-2对我们的地方、国家和全球的影响，我们的工作是迫切需要的。 社区及其对数百万已经或将来将发展的人的潜在影响 COVID 19感染通过揭示机制，分子靶点和可能导致的潜在药物 直接用于开发新的抗病毒治疗和疗法。

Project summary In late 2019, COVID-19, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) emerged in Wuhan, China and has rapidly impacted almost all countries around the world. Officially declared a global pandemic by the WHO, COVID-19 is a worldwide emergency and by million United with directly , current in vitro model platforms are so distinct from human infection that they may not capture key components of viral infection or virus-host interactions. May 29, 2020, over 5.8 COVID-19 cases were reported with over 360,000 deaths globally. Although originating in China the States has emerged as an epicenter of this pandemic with over 1.75 million COVID-19 cases reported over 103,000 deaths. Unfortunately there is no vaccine that can prevent SARS-CoV-2 infection or robust activing antivirals that can mitigate infection or alter disease progression. Moreover Given this local, national, and global emergency our near-term goal is on the development of novel and robust experimental cell culture models, virological tools, and to identify novel therapeutics for SARS-CoV-2 treatment. Our long-term goal is to elucidate the complex interactions and mechanisms underlying SARS-CoV-2 infection and host response. Given that our institution has been at the center of the COVID-19 pandemic here in the U.S. we have generated a wide database of clinical data that has revealed that a high prevalence of initial COVID- 19 presentations are with GI manifestations with over one-half of patients noted to have biochemical evidence of liver injury at presentation. The impact of SARS-CoV-2 infection on hepatocellular and cholangiocyte function remains unclear. To address these knowledge gaps we have generated several novel technologies and have assembled a robust team with complimentary expertise in stem cell biology, tissue engineering and virology, chemical screening and stem cell biology, and in virology/BSL3 expertise. We aim to identify drug candidates that impact SARS-CoV-2 viral infection while we evaluate host-virus interactions. Our work is urgently needed given the impacts SARS-CoV-2 has had on our local, national, and global communities and its potential impact on millions of people who already, or will in the future will develop COVID19 infection by shedding light on mechanisms, molecular targets, and potential drugs that could lead directly to the development of new antiviral treatments and therapies.